Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today ...
In other recent news, Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, delivering results that surpassed expectations. The company posted an earnings per share (EPS) of -$0.21, ...
Great. Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. We're a pleasure to have Ben Taylor, CFO of Recursion for a fireside chat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results